Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network
Insulin-like growth factor-binding protein 2 (IGFBP2) is increasingly recognized as a glioma oncogene, emerging as a target for therapeutic intervention. In this study, we used an integrative approach to characterizing the IGFBP2 network, combining transcriptional profiling of human glioma with validation in glial cells and the replicationcompetent ASLV long terminal repeat with a splice acceptor/tv-a glioma mouse system. We demonstrated that IGFBP2 expression is closely linked to genes in the integrin and integrin-linked kinase (ILK) pathways and that these genes are associated with prognosis. We further showed that IGFBP2 activates integrin β1 and downstream invasion pathways, requires ILK to induce cell motility, and activates NF-kB. Most significantly, the IGFBP2/integrin/ILK/NF-kB network functions as a physiologically active signaling pathway in vivo by driving glioma progression; interfering with any point in the pathway markedly inhibits progression. The results of this study reveal a signaling pathway that is both targetable and highly relevant to improving the survival of glioma patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Holmes, Kristen M. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological sciences |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
JST092559956 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | JST092559956 | ||
| 003 | DE-627 | ||
| 005 | 20240117001824.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 151228s2012 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)JST092559956 | ||
| 035 | |a (JST)41506975 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Holmes, Kristen M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Insulin-like growth factor-binding protein 2 (IGFBP2) is increasingly recognized as a glioma oncogene, emerging as a target for therapeutic intervention. In this study, we used an integrative approach to characterizing the IGFBP2 network, combining transcriptional profiling of human glioma with validation in glial cells and the replicationcompetent ASLV long terminal repeat with a splice acceptor/tv-a glioma mouse system. We demonstrated that IGFBP2 expression is closely linked to genes in the integrin and integrin-linked kinase (ILK) pathways and that these genes are associated with prognosis. We further showed that IGFBP2 activates integrin β1 and downstream invasion pathways, requires ILK to induce cell motility, and activates NF-kB. Most significantly, the IGFBP2/integrin/ILK/NF-kB network functions as a physiologically active signaling pathway in vivo by driving glioma progression; interfering with any point in the pathway markedly inhibits progression. The results of this study reveal a signaling pathway that is both targetable and highly relevant to improving the survival of glioma patients. | ||
| 540 | |a copyright © 1993-2008 National Acadamy of Sciences of the United States of America | ||
| 650 | 4 | |a Health sciences |x Medical conditions |x Diseases |x Neoplasia |x Germ cell and embryonal neoplasms |x Glioma | |
| 650 | 4 | |a Physical sciences |x Chemistry |x Chemical compounds |x Chemicals |x Polymers |x Biopolymers |x Proteins |x Membrane proteins |x Cell surface receptors |x Integrins | |
| 650 | 4 | |a Biological sciences |x Biology |x Cytology |x Cell biology |x Cells |x Cultured cells |x Cell lines | |
| 650 | 4 | |a Health sciences |x Medical conditions |x Diseases |x Neoplasia |x Tumors | |
| 650 | 4 | |a Biological sciences |x Biology |x Genetics |x Molecular genetics |x Genes | |
| 650 | 4 | |a Biological sciences |x Biology |x Zoology |x Animals |x Mammals |x Rodents |x Mice | |
| 650 | 4 | |a Biological sciences |x Biology |x Cytology |x Cell biology |x Cell physiology |x Cell motility | |
| 650 | 4 | |a Health sciences |x Medical conditions |x Diseases |x Neoplasia |x Cancer | |
| 650 | 4 | |a Health sciences |x Medical treatment | |
| 650 | 4 | |a Biological sciences |x Biology |x Genetics |x Molecular genetics |x Genetic code |x Antisense elements |x Antisense RNA |x Small interfering RNA | |
| 655 | 4 | |a research-article | |
| 700 | 1 | |a Annala, Matti |e verfasserin |4 aut | |
| 700 | 1 | |a Chua, Corrine Y. X. |e verfasserin |4 aut | |
| 700 | 1 | |a Dunlap, Sarah M. |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yuexin |e verfasserin |4 aut | |
| 700 | 1 | |a Hugen, Niek |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Lynette M. |e verfasserin |4 aut | |
| 700 | 1 | |a Cogdell, David |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Limei |e verfasserin |4 aut | |
| 700 | 1 | |a Nykter, Matti |e verfasserin |4 aut | |
| 700 | 1 | |a Hess, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Fuller, Gregory N. |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
| 773 | 1 | 8 | |g volume:109 |g year:2012 |g number:9 |g pages:3475-3480 |
| 856 | 4 | 0 | |u https://www.jstor.org/stable/41506975 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_JST | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2012 |e 9 |h 3475-3480 | ||